An Inflammation‐Targeting Engineered Probiotic Escherichia coli Nissle 1917 with High Anti‐TNF‐α Nanobody Secretion Efficacy Alleviates Ulcerative Colitis
Advanced Science · 2025-12 · 12 (46)
DOI: 10.1002/advs.202512360 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 29.09.2025. Verfasst von Siqi Hua und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Biopharmacy, China Pharmaceutical University, Nanjing, 211198, P. R. China. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Probiotics, Escherichia coli, Tumor Necrosis Factor-alpha. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Changzhou Municipal Department of Science and Technology.
Abstract (Originalsprache)
The probiotic Escherichia coli Nissle 1917 (EcN), clinically used for ulcerative colitis (UC) due to its safety and genetic tractability, exhibits limited therapeutic efficacy owing to poor targeting and colonization at inflamed sites. Phosphatidylserine (PS) exposure increases on apoptotic colon epithelial cells during UC progression, suggesting PS‐targeting could enhance EcN localization. Here, EcN is engineered to surface‐display Annexin A5 (ANXA5), a PS‐binding protein, to improve inflammation targeting and colonization. Since TNF‐α drives UC pathogenesis and anti‐TNF‐α biologics face cost and safety limitations, the secretion‐hindering lpp gene is concurrently knocked out in ANXA5‐expressing EcN, creating the inflammation‐targeted, secretion‐enhanced EcN Δlpp ::A5. This base strain is further modified to secrete an anti‐TNF‐α nanobody (aTN), generating EcN Δlpp ::A5‐aTN. Both engineered strains demonstrate significantly stronger colonic colonization versus wild‐type EcN, effectively attenuating oxidative stress‐mediated epithelial apoptosis, restoring mucosal barriers, improving immune‐microbiota balance, and alleviating murine colitis. EcNΔ lpp ::A5‐aTN shows superior efficacy to EcNΔ lpp ::A5. This study develops an engineered EcN system with enhanced targeting, colonization, and secretion. By efficiently delivering anti‐TNF‐α nanobodies, EcNΔ lpp ::A5‐aTN exhibits strong therapeutic potential for UC, overcoming limitations that hinder the clinical application of wild‐type EcN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biopharmacy, China Pharmaceutical University, Nanjing, 211198, P. R. China.
- State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 211198, P. R. China.
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, P. R. China.
- Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, SE1 9RT, UK.
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 21205, USA.
- Faculty of Pharmaceutical Sciences, Xinxiang Medical University, Xinxiang, 453004, P. R. China.
ORCID-Profile: Bo Zhu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Changzhou Municipal Department of Science and Technology
Zitieren
APA
Hua, S., Li, K., Shang, P., Liu, L., Pan, J., Zhu, B., & Hua, Z. (2025). An Inflammation‐Targeting Engineered Probiotic Escherichia coli Nissle 1917 with High Anti‐TNF‐α Nanobody Secretion Efficacy Alleviates Ulcerative Colitis. Advanced Science, 12(46). https://doi.org/10.1002/advs.202512360
Vancouver
Hua S, Li K, Shang P, Liu L, Pan J, Zhu B, et al. An Inflammation‐Targeting Engineered Probiotic Escherichia coli Nissle 1917 with High Anti‐TNF‐α Nanobody Secretion Efficacy Alleviates Ulcerative Colitis. Advanced Science. 2025;12(46). doi:10.1002/advs.202512360
BibTeX
@article{Hua2025,
author = {Hua, Siqi and Li, Kaiqiang and Shang, Pengyou and Liu, Lina and Pan, Jiayu and Zhu, Bo and Hua, Zichun},
title = {An Inflammation‐Targeting Engineered Probiotic Escherichia coli Nissle 1917 with High Anti‐TNF‐α Nanobody Secretion Efficacy Alleviates Ulcerative Colitis},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {46},
doi = {10.1002/advs.202512360}
}
EUVIMED